Heat shock protein vaccines against glioblastoma: from bench to bedside.
Heat shock protein vaccines against glioblastoma: from bench to bedside.
复制标题
对胶质母细胞瘤的热休克蛋白疫苗：从长凳到床边。
DOI：
10.1007/s11060-015-1837-7
复制
发表时间：
2015-07
影响因子：
3.9
通讯作者：
Parsa AT
中科院分区：
文献类型：
--
作者：
Ampie L;Choy W;Lamano JB;Fakurnejad S;Bloch O;Parsa AT
目前可用于治疗胶质母细胞瘤的辅助治疗方案广泛无效，预后不良。传统治疗策略的进步仅使总生存率略有改善。免疫疗法通过引发能够产生持续抗肿瘤应答同时最小化全身毒性的肿瘤特异性免疫应答，在GBM治疗中仍然是一种有前景的佐剂。热休克蛋白（HSP）作为细胞内伴侣蛋白发挥作用，并参与先天性和适应性免疫系统的激活。由来源于自体肿瘤的HSP-肽复合物配制的疫苗已经应用于胶质母细胞瘤的免疫治疗领域。I期和II期临床试验的结果令人鼓舞。本文就HSP在细胞功能和免疫中的作用及其在胶质母细胞瘤治疗中的应用作一综述。
Current adjuvant treatment regimens available for the treatment of glioblastoma are widely ineffective and offer a dismal prognosis. Advancements in conventional treatment strategies have only yielded modest improvements in overall survival. Immunotherapy remains a promising adjuvant in the treatment of GBM through eliciting tumor specific immune responses capable of producing sustained antitumor response while minimizing systemic toxicity. Heat Shock Proteins (HSP) function as intracellular chaperones and have been implicated in the activation of both innate and adaptive immune systems. Vaccines formulated from HSP-peptide complexes, derived from autologous tumor, have been applied to the field of immunotherapy for glioblastoma. The results from the phase I and II clinical trials have been promising. Here we review the role of HSP in cellular function and immunity, and its application in the treatment of glioblastoma.